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Phase Ia/Ib Chemo-Radiation Trial of Gemcitabine and
Dose-Escalated Thoracic Radiation in Patients with Stage III
A/B Non-small Cell Lung Cancer
A. William Blackstock, MD,* Coty Ho, MD,† Jerome Butler, MD,* June Fletcher-Steede, BA,*
L. Douglas Case, PhD,‡ William Hinson, PhD,* and Antonius A. Miller, MD†
Introduction: The safety of dose-escalated thoracic radiation con-
current with gemcitabine in patients with inoperable stage III non-
small cell lung cancer has not been studied.
Patients and Materials: The maximal tolerated dose of 35 mg/m2
twice-weekly gemcitabine and concurrent standard thoracic radia-
tion was established in a previous phase Ia trial. In this study, a
second patient cohort (phase Ib) received twice-weekly gemcitabine
concurrent with three-dimensional dose-escalated thoracic radiation
(60-74 Gy) after two cycles of induction chemotherapy: gemcitabine
(1000 mg/m2) day 1 and 8 and carboplatin (area under the curve
5.0-5.5) day 1 every 21 days.
Results: Twenty-three patients were entered in the phase Ib portion
of this trial. Grade III/IV hematologic toxicity was primarily throm-
bocytopenia (22%) and neutropenia (26%). Grade III/IV esophageal
toxicities occurred in 17% of patients, and grade III radiation
pneumonitis/dyspnea was observed in 7 of 23 patients. The median
and 2-year survival for phase Ib patients were 17.4 months and 32%,
respectively. The overall 1- and 2-year survival for all 39 patients
(16 phase Ia, 23 phase Ib) was 69% and 32%, respectively.
Conclusions: Combining 74-Gy thoracic radiation and concurrent
gemcitabine is feasible, but the use of this regimen should be limited
to the confines of a clinical trial. A randomized phase II trial through
the Cancer and Leukemia Group B is underway to further evaluate
the efficacy of this regimen.
Key Words: Gemcitabine, Radiation, Lung cancer, Locally ad-
vanced, Dose-escalation.
(J Thorac Oncol. 2006;1: 434–440)
Lung cancer is the leading cause of cancer-related death inthe United States and North America.1,2 Randomized trials
have suggested an overall improved survival and local control
advantage with the concurrent administration of radiation and
chemotherapy for good performance patients with stage III
non-small cell lung cancer (NSCLC), and this strategy re-
flects the current standard of care.3,4 Unfortunately, the cure
rate for patients with inoperable NSCLC remains less than
20% despite more than 30 years of clinical trials. Although
novel chemotherapeutic agents and strategies continue to
evolve, the use of concurrent gemcitabine and thoracic radi-
ation has only been studied in a limited fashion5–11 and, to our
review, not in the setting of dose-escalated thoracic radiation.
Two-dimensional radiotherapy delivered alone to con-
ventional doses in NSCLC has been ineffective at sterilizing
local tumors. The delivery of higher doses of thoracic radia-
tion to improve local control using traditional two-dimen-
sional treatment planning is limited by concerns for normal
tissue tolerance and poor tumor targeting. The development
of three-dimensional (3-D) conformal radiation treatment
planning provides more accurate dose targeting via the direct
transfer of 3-D anatomic information from diagnostic-quality
scans into the planning process. This technique also provides
dose-volume histograms, which function to estimate the
probability of normal tissue complications. Related data from
Socinski et al.12 support the notion that 3-D conformal tho-
racic radiation in the setting of concurrent chemotherapy may
prove important. In the Socinski et al. phase II study, patients
received concurrent carboplatin/paclitaxel and dose-escalated
thoracic radiation to 74 Gy. The overall response rate was
52%, whereas the median and 2-year survival rates were an
encouraging 26 months and 52%.
Gemcitabine is an active single agent in the treatment
of NSCLC13,14 with established radiation-sensitizing proper-
ties.15–27 A phase II study from Lund et al. among patients
with metastatic NSCLC observed systemic activity with a
twice-weekly (90 mg/m2) dosing schedule of gemcitabine.28
These data support our strategy of combining radiation with
twice-weekly gemcitabine for the treatment of patients with
stage III NSCLC. Because the phase Ia gemcitabine toxicity
portion of this trial has been previously reported, we focused
on reporting the toxicities observed in the phase Ib patient
cohort, performed an analysis of the radiation-related pulmo-
nary and esophageal events that occurred, and report the
overall long-term survival for all patients treated (phase Ia
and Ib).
*Department of Radiation Oncology, †Section of Hematology and Oncol-
ogy, and ‡Department of Public Health Sciences, Wake Forest University
Comprehensive Cancer Center, Winston-Salem, North Carolina
Address for correspondence: A. William Blackstock, M.D., Department of
Radiation Oncology, Wake Forest University, Medical Center Blvd.,
Winston-Salem, NC 27516. E-mail: ablackst@wfubmc.edu
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0105-0434
Journal of Thoracic Oncology • Volume 1, Number 5, June 2006434
PATIENTS AND METHODS
Patient Population
Patients aged 18 to 70 years with a histologically
confirmed diagnosis of inoperable stage IIIA / IIIB NSCLC
were eligible. Although the use of mediastinoscopy for stag-
ing declined and the use of 18-fluoro-deoxy-glucose-positron
emission tomography (FDG-PET) increased over the span of
this trial, all patients were required to meet standard comput-
erized tomography (CT) criteria to be eligible. Inclusion
criteria were the following: Eastern Cooperative Oncology
Group (ECOG) performance status (PS) 0-1; no prior thoracic
radiation or chemotherapy; adequate bone marrow (absolute
neutrophil count 1,500 cells/mm3, platelet count 100,000
cells/mm3, and hemoglobin 10 g/dL); kidney function (se-
rum creatinine  1.5 X normal), and liver function (serum
total bilirubin  2 mg/dL). A minimal pretreatment forced
expiratory volume in 1 second (FEV-1) of 1.0 L was also
required. Patients with prior malignancy were ineligible for
the study, with the exception of those who had non-mela-
noma skin cancer, in situ cancer of the cervix, or other cancer
for which the patient had been disease-free for 5 years.
All patients provided written informed consent accord-
ing to federal and institutional guidelines. Institutional review
board approval was obtained before the initiation of this trial.
Treatment
We established 35 mg/m2 twice-weekly gemcitabine as
the recommended dose for further evaluation and delivered it
intravenously on either Monday and Thursday or Tuesday
and Friday during radiation therapy.29 During the radiation
dose-escalation portion of this study, three to six patients
were enrolled in a step-wise fashion to receive a total dose of
60, 66, 70, and 74 Gy. The initial dose of 40 Gy was delivered
in 200-cGy fractions, followed by dose escalation in the boost
volumes (20, 26, 30, and 34 Gy, respectively) in 200-cGy
daily fractions. All patients treated during dose escalation
received two cycles of induction chemotherapy: gemcitabine
(1000 mg/m2) on day 1 and 8, along with carboplatin (area
under the curve 5.0-5.5) on day 1. Each induction cycle
consisted of 2 weeks of treatment, followed by a 1-week
break. After induction chemotherapy, concurrent twice-
weekly gemcitabine and radiation were delivered as outlined
in the treatment schema (Figure 1). This trial, which uses an
induction chemotherapy strategy, was designed before the
preponderance of data suggesting an advantage for immediate
concurrent chemo-radiation became available.
Radiation Treatment Planning
Patients underwent a volumetric treatment-planning CT
scan (non-contrasted) in the treatment position on a flat table.
Contiguous CT slices 2.5–5 mm thick were obtained through
regions harboring gross primary tumor or nodal disease, and
5– to 10-mm slices were used through the remaining regions.
In general, the scanned volume encompassed the entire bilat-
eral lung volume between the cricoid cartilage superiorly and
the lower edge of the liver inferiorly. The gross tumor volume
(GTV) and planning target volumes (PTV) were delineated
according to the International Commission on Radiation
Units and Measurements (ICRU) Report 50 guidelines. The
GTV included the primary tumor and any enlarged regional
lymph nodes (1.0 cm in the short axis) and outlined using
both lung and mediastinal CT window settings. 18Fluorode-
oxy-glucose positron emission tomography (FDG-PET) im-
aging was not used in this study to define the GTV. The
clinical target volume (CTV) was the GTV plus 2.0 cm for all
borders, with the exception of the interface of the primary
lesion and normal pulmonary parenchyma. The CTV in this
region could be a minimum of 0.5 cm. A larger CTV into
pulmonary parenchyma was allowed at the investigators’
discretion if significant motion was noted in the primary
lesion (determined with fluoroscopy). The PTV included the
CTV-1 plus 1.0 cm at all borders. During the off-cord boost
treatment, the CTV included the GTV plus 1.0 cm with 0.5
cm for the interface into normal pulmonary parenchyma, and
the PTV was composed of the CTV plus 1.0 cm at all borders.
The required normal tissue delineation included the right
lung, left lung, heart, spinal cord, and esophagus. In this
single institution experience, the principal investigator and
lead physicist reviewed each patient’s contours.
FIGURE 1. Treatment schema:
phase Ib radiation dose escalation.
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Doses were prescribed at or near the isocenter in the
central part of the PTV. The 95% isodose line was to cover
the PTV using plans without corrections for lung heteroge-
neity. The maximal PTV dose was not to exceed 110%. All
fields were treated for each fraction delivered, and the spe-
cific design and configuration of the fields were individual-
ized based on the volume and location of the disease. The
spinal cord dose was limited to 45 Gy. The total lung volume
was defined as the volume of both lungs (combined pair
organ) minus the GTV. The V10, V20, and V30 in our study
were defined as the total lung volume receiving 10, 20,
and 30 Gy, respectively, in the initial radiation portals.
Although no effort was made to limit the tumor size, lung
V20, or length of esophagus irradiated, we did restrict the
elective mediastinal radiation to the “next echelon” of nodes
beyond those clinically involved in an attempt to limit the
radiation volumes.
Evaluation
Weekly complete blood cell counts were required dur-
ing treatment, and the use of myeloid growth factors was
discouraged but allowed per American Society of Clinical
Oncology (ASCO) guidelines. Patients were evaluated for
response and toxicity clinically and radiographically (CT)
every 3 months the first year, every 4 months the next 2 years,
every 6 months for 2 years, and then at the discretion of the
physician. Patients were removed from the protocol for dis-
ease progression; unacceptable toxicity as assessed by the
patient and investigators; development of intercurrent, non–
cancer-related illnesses precluding continued treatment; or
patient request. Site(s) of first relapse and cause of death were
ascertained. Because the Response Evaluation Criteria in
Solid Tumors (RECIST) criteria had not been established
when this trial was activated,30 tumor responses were as-
sessed using standard World Health Organization (WHO)
response criteria.31 All responses were determined by an
independent external reviewer and were confirmed 8 weeks
after initial documentation of the response. Toxicities were
graded according to the NCI Common Toxicity Criteria,
version 2.0.32
Statistical Design and Analyses
The primary end point of the phase Ib portion of the
study was to establish the feasibility of delivering concurrent
gemcitabine and dose-escalated thoracic radiation. T-tests
were used to assess differences in V20 and FEV-1 between
patients experiencing acute grade III pneumonitis/dyspnea
and those who did not. We used 2, logistic regression, and
Fisher’s exact tests to compare the proportion of patients who
developed toxicities based on cut points of the pulmonary and
esophageal parameters and to assess which pretreatment pa-
tient characteristics were associated with tumor response.
Kaplan-Meier methods were used to estimate the time to
progression and survival distributions. Log rank tests were
used to determine which characteristics were associated with
these outcomes.
RESULTS
Patient Characteristics
The phase Ib radiation dose-escalation portion of this
study was activated in October 2000 and closed in January
2002. Twenty-three patients were entered during the phase Ib
portion of the study. A total of 40 patients were accrued to the
entire study (phase Ia and Ib); however, one patient was
ineligible because of stage IV disease and was not included in
this analysis. The patient characteristics for the 23 phase Ib
patients are listed in Table 1. Most patients were white (87%)
and male (57%). Age ranged from 51 to 81 years, with a
median of 66 years. Most patients were highly ambulatory
(PS  0 for 70%), and approximately half had stage IIIa
disease.
Toxicity
The maximal toxicities for the Ib portion of the trial are
shown in Table 2. The maximal tolerated dose (MTD) in the
phase Ib portion of this trial was defined as the highest
radiation dose at which no more than one patient developed
a radiation-related grade  4 toxicity and no more than two
patients experienced a grade3 toxicity at any radiation dose
level. The highest planned radiation dose level (74 Gy) was
achieved but with moderate toxicity; therefore, the MTD of
radiation was not determined. For all 39 evaluable patients,
grade III/IV radiation-associated esophagitis during or within
30 days of completion of the chemo-radiation was observed
in 13% and 5% of patients, respectively. The median length
( standard error) of irradiated esophagus (full circumfer-
ence) for all patients was 11.5  0.54 cm versus 13.1  0.81
cm for patients experiencing a grade III/IV esophagitis (P 
0.17). Whereas grade III radiation pneumonitis/dyspnea was
clinically important and observed in 11 of 39 patients (28%),
no grade IV or grade V acute or late pulmonary complications
TABLE 1. Patient characteristics
Characteristic Phase 1b
Total eligible 23
Age (yr)
Median (range) 66 (51–81)
60 Years 17 (74)
Gender
Male 13 (57)
Female 10 (43)
Ethnicity
African-American 3 (13)
Other 20 (87)
Performance status
0 16 (70)
1 6 (26)
2 1 (4)
Stage
IIIA 11 (48)
IIIB 12 (52)
Values are n (%) or median (range).
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were observed. The acute grade III pneumonitis/dyspnea
observed were all determined either near the completion of or
within 30 days of completion of the chemo-radiation. Data
for correlating baseline pulmonary function, as determined by
the pretreatment FEV-1 using standard pulmonary function
testing and the V20, were available for 34 patients, of whom
11 experienced toxicity, and are presented in Figure 2. The
mean ( standard error) V20 was significantly higher for
patients experiencing a grade III pulmonary toxicity com-
pared with those who did not (30.0%  2.2% vs 22.4% 
1.4%) (P  0.01). However, the mean pretreatment FEV-1
for patients experiencing a pulmonary toxicity was only
slightly worse (1.7  0.16 L vs 2.0  0.14 L) (P  0.09). Of
the patients with a pre-treatment FEV-1 1.7 L, 50% (8 of
16) experienced an acute pulmonary toxicity, compared with
17% (3 of 18) of patients with better baseline pulmonary
function (P  0.05). The percent lung irradiated for patients
with poor lung function (FEV-1  1.7) was also significantly
greater, 27.5  1.7 versus 22.4  1.7 (P  0.05), potentially
contributing to the pulmonary toxicity observed. The seg-
mented line in Figure 2 was generated by fitting a logistic
regression and using the probability with the highest sum of
sensitivity and specificity for classifying a patient as having a
pulmonary toxicity. That probability was 40%; values above
the line have a greater than 40% probability of suffering a
pulmonary toxicity. This model correctly classifies 10 of 11
patients with toxicities (91% sensitivity) and 19 of 23 patients
without toxicity (83% specificity). Although V30 was not
predictive in this analysis, V10 was significantly higher in
those patients experiencing a pulmonary toxicity (34.5  2.9
vs 25.0  2.1) (P  0.02).
Response
Of the patients treated in the Ib portion of this trial,
70% (16 of 23) completed all planned therapy and were
evaluable for response. Complete and partial responses were
observed in 11% and 63% of patients, respectively. For the
entire 39-patient cohort, 30 patients (77%) completed all
planned therapy and were evaluable for response. One patient
discontinued therapy because of toxicity, three patients re-
fused additional treatment, and one patient with a significant
cardiac history suffered an unrelated myocardial infarction 1
day after registration. The best radiographic responses for the
34 evaluable patients are presented in Table 3. By CT criteria,
the complete and partial response rates were 9% and 65%,
respectively, for an overall response rate of 74% (95% CI,
56%–87%). Stable disease and progressive disease occurred
in six patients (18%) and three patients (9%), respectively.
Patient response was not associated with any of the charac-
teristics shown in Table 1.
TABLE 2. Grade III/IV toxicities during the chemo-radiation
dose escalation
Phase Ib N (%)
Total eligible 23
Toxicities Grade III Grade IV
Esophagitis (acute) 4 (17) 0
Nausea/vomiting 2 (9) 0
Pneumonitis/dyspnea (acute) 7 (30) 0
Neutropenia 4 (17) 2 (9)
Thrombocytopenia 3 (13) 2 (9)
Values are n (%).
FIGURE 2. Patients experiencing an acute grade III pulmo-
nary toxicity are represented by the open circles, whereas
patients with grade 0-II are represented by the closed circles.
The segmented line reflects the probability for a pulmonary
toxicity. Data points above the line have a greater than 40%
probability of experiencing a pulmonary toxicity. This model
correctly classifies 10 of 11 patients with toxicities (91% sen-
sitivity) and 19 of 23 patients without toxicity (83% specific-
ity). Grade III pneumonitis/dyspnea included patients with
radiographic changes and requiring oxygen and or dyspnea
at normal level of activity.
TABLE 3. Response and survival for the entire patient
cohort (phase Ia and phase Ib)
Phase Ia Phase Ib Total
Total eligible 16 23 39
Off treatment
Completed 14 (88) 16 (70) 30 (77)
Progression 1 (6) 2 (9) 3 (8)
Toxicity 1 (6) 0 (0) 1 (3)
Doctor decision 0 (0) 3 (13) 3 (8)
Died 0 (0) 2 (9) 2 (5)
Tumor response
Evaluable 15 19 34
Best response
Complete 1 (7) 2 (11) 3 (9)
Partial 10 (67) 12 (63) 22 (65)
Stable 3 (20) 3 (16) 6 (18)
Progressive 1 (7) 2 (11) 3 (9)
Survival
Deaths 14 20 34
Median (mo)
(95% C.I.)
16.0
(11.1–26.2)
17.4
(13.7–25.4)
16.0
(13.7–21.3)
1-year estimate (SE) 0.69 (0.12) 0.70 (0.10) 0.69 (0.07)
2-year estimate (SE) 0.31 (0.12) 0.32 (0.10) 0.32 (0.07)
Values are n (%) or median (range).
Journal of Thoracic Oncology • Volume 1, Number 5, June 2006 Gemcitabine and Thoracic Radiation in Stage III A/B NSCLC
Copyright © 2006 by the International Association for the Study of Lung Cancer 437
Survival Analysis
Although limited by the phase I nature of this trial, the
Kaplan-Meier estimates for survival and time to progression
for all patients are displayed in Figure 3. With a median
follow-up of 41 months, the overall survival rates at 1 and 2
years were 69% and 32%, respectively. The median survival
time for the 23 patients in the Ib portion was 17.4 months. For
the entire patient cohort, five patients (13%) remain alive;
two patients (12%) treated in the phase Ia portion and three
patients (13%) treated in the phase Ib radiation dose-escala-
tion portion. Six patients (15%) experienced local regional
failure either alone or as a component of the first site of
recurrence.
DISCUSSION
The efficacy and acceptable toxicity of gemcitabine,
either as a single agent or in combination with other chemo-
therapy, has been established in numerous clinical trials in
advanced-stage NSCLC.33–39 The experience combining
gemcitabine and radiation in the treatment of patients with
stage III disease, however, is limited. Vokes et al.9 reported a
three-arm randomized phase II trial, in which one arm con-
sisted of two cycles of induction gemcitabine/cisplatin che-
motherapy, followed by concurrent gemcitabine/cisplatin
with the thoracic radiotherapy. During the 6.5 weeks of
chemo-radiation, the gemcitabine (600 mg/m2) was given
during weeks 1, 2, 4, and 5. Of the 180 patients enrolled, 63
were randomized to the gemcitabine treatment arm. The
median survival for this arm of the study was an encouraging
18.4 months, with an estimated 1-year survival of 68%.
Toxicity during the concurrent treatment with gemcitabine
included grade III/IV esophagitis in 51% of patients, whereas
grade III/IV dyspnea was seen in 14% of patients. Table 4
provides a sense of the variety of experiences thus far
reported with gemcitabine combined with thoracic radiation.
Further evaluation of these trials provides some insight
as to why there was significant variability in the esophageal
toxicities observed among the studies. The study by Vokes et
al.9 used standard radiation treatment parameters with formal
coverage of the entire mediastinum “from the level of the
aortic arch to 4 cm below the carina.” In contrast, the study by
Burmeister et al.40 and van Putten et al.41 mandated a maxi-
mal length (15 cm) of esophagus that could be irradiated, and
the van Putten trial also mandated a maximum field size
(2000 cm3). The trial by Trodella et al.42 restricted the
radiation volumes to coverage of gross disease plus dosimet-
ric margin. It should be noted that the mean pretreatment
FEV-1 for patients in the Trodella et al. trial was more than
2 L. In a similar but expanded fashion, the initial radiation
volumes in our trial included coverage of all gross disease
and the next echelon of uninvolved lymph nodes plus dosi-
metric margin. Unlike the van Putten et al. trial, we did not
use dose volume constraints in our study. Unlike the Trodella
et al. study, our mean patient pretreatment FEV-1 was less
than 2 L, which may, in part, explain why our grade III
pulmonary toxicities were increased.
Although the median length of esophagus (full circum-
ference) treated in our patients experiencing grade III/IV
esophagitis was increased, this difference was not statistically
significant. As recently reviewed by Bradley and Movsas,43
the parameters that predict the development of acute radiation
esophagitis are potentially numerous and complex (maxi-
mal esophageal dose, the mean esophageal dose, percent of
esophagus receiving certain threshold doses, etc). As sug-
gested by Zahn et al.,44 there is no consensus as to which
dosimetric parameter is most predictive, and a possible lim-
itation of these studies is the anatomic/functional accuracy of
esophageal contours defined on serial axial images. Given the
FIGURE 3. Overall survival and progression-free survival
(Kaplan-Meier).
TABLE 4. Chemo-radiation trials using gemcitabine
Investigator n
Radiation
dose (Gy)
Gemcitabine
(mg/m2/wk)
CR/PR
(%) Median PTV (cm3)
Grade III/IV
esophagitis (%)
Grade III/IV dyspnea/
pneumonitis (%)
van Putten et al.40 27 60.0 300 63 760 (289–1718) 4 4
Blanco et al. 38 34 68.4 300 67 2275 39 17
Burmeister et al. 39 18 30.0 100-150 88 2275 (1688–4631) 11 0
Trodella et al. 41 36 50.4 100-375 67 NS 5a 5
Divers et al. 49 51 60.0 150-300 75 NS 27 14
Vokes et al. 9 63 66.0 600 68 NS 52 14
Wake Forest University 40 60–74 70 74 955 (667–2206) 18 31
a Including three grade 5 toxicities.
Blackstock et al. Journal of Thoracic Oncology • Volume 1, Number 5, June 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer438
vast number of unproven parameters to measure, we limited
our analysis and were not surprised that our study did not
establish a linear relationship using the single parameter of
length of esophagus irradiated.
As shown in Table 4, it seems the pulmonary toxicity in
our trial was generally higher compared with other studies of
radiation and concurrent gemcitabine. Because the toxicities
associated with gemcitabine given concurrently with radia-
tion may be related to gemcitabine dosing schedule and
volume of normal tissue in the radiation field, we tried to
elucidate potential reasons for the pulmonary toxicity seen in
this study and reviewed several relevant preclinical studies.
Joschko et al.20 evaluated radiation plus once-weekly gem-
citabine versus twice-weekly gemcitabine in a human squa-
mous xenograft model and found that, although the twice-
weekly schedule had significant anti-tumor effects, it also
seemed to be more toxic to the normal tissues. This obser-
vation was also reported by Mason et al. in a gut normal
tissue model.24 In contrast, Fields et al.19 found a higher
therapeutic index with twice-weekly gemcitabine and radia-
tion compared with once-weekly gemcitabine. To discern the
clinical relevance of our twice-weekly dosing schedule (with-
out radiation) and the risk of pulmonary toxicity, we re-
viewed the phase II study from Lund et al.28 In this trial, 90
patients (81 evaluable) with metastatic NSCLC received
twice-weekly gemcitabine at a dose of 90 mg/m2. This
regimen resulted in an overall response rate of 19%. Inter-
estingly, gemcitabine-related pulmonary dyspnea was ob-
served in 16% of patients. This is slightly higher than the 5%
to 12% reported from trials of weekly gemcitabine delivered
in combination with a variety of other agents.45–48 From these
data, one could hypothesize that the acute pulmonary toxicity
associated with radiation given concurrently with gemcitab-
ine is related to sensitization of normal pulmonary paren-
chyma with the twice-weekly gemcitabine dosing schedule.
There are several additional factors to consider in
clarifying the differences in pulmonary toxicity observed in
the trials listed in Table 4. As previously stated, the trials by
Trodella and van Putten et al. both mandated limited radiation
volumes. In addition, the study by van Putten et al. restricted
the enrollment to patients with a baseline FEV-1 1.5 L,
whereas the median pretreatment FEV-1 in the study by
Trodella et al. was 2.08 L. In the study by Vokes et al.,
patients only received four doses of gemcitabine during the
6.5 weeks of radiation, with a significant cohort of patients
receiving fewer than four doses because of toxicity. Our
study allowed enrollment of patients with a baseline FEV-1
1.0 L and did not mandate a maximal radiation volume. As
shown in Figure 2, we attempted to discern whether we could
establish a relationship between the volume of lung irradiated
and the subsequent development of radiation pneumonitis/
dyspnea. In this analysis, the mean V10 and V20 lung volumes
for those patients experiencing a pulmonary toxicity were
greater, and this difference was statistically significant. These
findings are consistent with the article from Divers et al.,
which also reports an association between V15 and V20 and
the subsequent development of grade 3 acute pulmonary
toxicity.49 In our logistic regression analysis, V20 and base-
line pulmonary function discriminated well between patients
with and without grade 3 pulmonary events (segmented line
in Figure 2).
In conclusion, 74-Gy thoracic radiation and concurrent
gemcitabine are feasible, but the use of this combination
should be limited to the confines of a clinical trial. At present,
CALGB investigators are examining the efficacy of this
treatment strategy in a randomized phase II study.
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